Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$21.00 USD
+0.75 (3.70%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $21.02 +0.02 (0.10%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
AKRO 21.00 +0.75(3.70%)
Will AKRO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for AKRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKRO
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
AKRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
Wall Street Analysts Predict a 58.87% Upside in Akero Therapeutics, Inc. (AKRO): Here's What You Should Know
Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus
Other News for AKRO
Akero Therapeutics reinstated with a Neutral at BofA
Hepion ends Phase 2 study for NASH drug due to cash restraints
Madrigal announces US launch of NASH/MASH drug Rezdiffra
Akero Therapeutics' EFX Data Warrants Caution
Inventiva Phase 2 study for MASH drug meets primary endpoint